Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Cash from Financing Activities (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of Cash from Financing Activities data on record, last reported at -$27000.0 in Q2 2024.

  • For Q2 2024, Cash from Financing Activities rose 97.03% year-over-year to -$27000.0; the TTM value through Dec 2024 reached $104.8 million, up 21.65%, while the annual FY2025 figure was $275000.0, 99.74% down from the prior year.
  • Cash from Financing Activities reached -$27000.0 in Q2 2024 per SGMT's latest filing, down from $104.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $104.8 million in Q1 2024 and bottomed at -$910000.0 in Q2 2023.